MedPath

Ayurvedic treatment for hypothyroidism

Not yet recruiting
Conditions
Hypothyroidism, unspecified,
Registration Number
CTRI/2019/08/020697
Lead Sponsor
Dr Vishala R Dodke
Brief Summary

Title- an open randomised controlled clinical trail to study the triphala yog in the management of galganda in comparision with thyroxime with special refrence to hypothyroidism.



Trial group - triphala yog



Dose of triphala yog - 100ml orally



Control group - tab thyroxime



Dose of thyroxine - 50 to 100 mcg as per severity of symptoms



Assessment criteria-



Objective criteria - serum TSH, serum t3, serum t4 level, will be done before and after the trial



Subjective criteria - weight gain, amenorrhea, hoarseness of voice, loss of appetite, constipation, somnolence, dyspnoea, debility, dryness, hair loss

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
77
Inclusion Criteria

Diagnosed patients of hypothyroidism Patients of either gender Age > 18 years to 80 years Serum ultrasensitive TSH level >5 micro iu/ml.

Exclusion Criteria

Immunocompromised patients or patients on immunosuppresive drugs Patients suffering from life threating disease Pregnancy and lactating mother K/C/O Thyroid neoplasia, congenital hypothyroidism Progressive cause of myxoedema coma Infiltrative disorders like sarcoidosis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Triphalayog more effective in management of Hypothyroidsm than Thyroxineonce in month for three months
Secondary Outcome Measures
NameTimeMethod
Triphalayog does not have effect in management of HypothyroidsmOnce in a month for three months

Trial Locations

Locations (1)

Ymt ayurvedic medical college and hospital

🇮🇳

Raigarh, MAHARASHTRA, India

Ymt ayurvedic medical college and hospital
🇮🇳Raigarh, MAHARASHTRA, India
Dr vishala dodke
Principal investigator
8407934211
dodkevishala@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.